Literature DB >> 24634526

Orogastric administration of crushed darunavir tablets for a critically ill patient.

Catherine H Kim1, Katie M Muzevich2, Patricia P Fulco3.   

Abstract

Entities:  

Year:  2014        PMID： 24634526      PMCID： PMC3952907          DOI： 10.4212/cjhp.v67i1.1321

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  14 in total

Review 1.  Medication administration through enteral feeding tubes.

Authors:  Nancy Toedter Williams
Journal:  Am J Health Syst Pharm       Date:  2008-12-15       Impact factor: 2.637

2.  Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.

Authors:  Anne B Taegtmeyer; Veronique Müller; Helen Kovari; Gerd A Kullak-Ublick; Natascia Corti
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

Review 3.  When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection.

Authors:  Chessa R Nyberg; Brooke Y Patterson; Meghan M Williams
Journal:  Top Antivir Med       Date:  2011 Aug-Sep

4.  Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.

Authors:  Alice K Pau; Scott R Penzak; Sarita D Boyd; Mary McLaughlin; Caryn G Morse
Journal:  Pharmacotherapy       Date:  2012-01       Impact factor: 4.705

5.  Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

Authors:  Uriel Sandkovsky; Susan Swindells; Ryan Moore; Edward P Acosta; Courtney V Fletcher
Journal:  Pharmacotherapy       Date:  2012-02       Impact factor: 4.705

Review 6.  Administration of antiretroviral medication via enteral tubes.

Authors:  Emily S Prohaska; Allison R King
Journal:  Am J Health Syst Pharm       Date:  2012-12-15       Impact factor: 2.637

7.  Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.

Authors:  Scott R Penzak; Elizabeth Formentini; Raul M Alfaro; Michael Long; Ven Natarajan; Joseph Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

8.  Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube.

Authors:  Mahoko Kamimura; Koji Watanabe; Masao Kobayakawa; Fuminori Mihara; Yoshihiro Edamoto; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  Intern Med       Date:  2009-06-15       Impact factor: 1.271

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Authors:  Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177
View more
  1 in total

1.  Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?

Authors:  Lisa Jane Frigati; Helena Rabie
Journal:  Children (Basel)       Date:  2022-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.